Abstract
Daphnoretin is an active constituent of Wikstroemia indica C.A. Mey., which is widely distributed in the northwest and southwest regions of China. Previous studies have shown that daphnoretin has anticancer effects on leukemia, osteosarcoma and uterine cervix cancer cells. However, the effect of daphnoretin on human lung cancer cells has yet to be elucidated. In the present study, daphnoretin was observed to inhibit A549 lung cancer cell proliferation in a concentration- and time-dependent manner. Fluorescent microscopy and flow cytometric analysis showed that daphnoretin induced A549 cell apoptosis in a concentration-dependent manner. Western blot analysis also revealed that daphnoretin induced apoptosis through the regulation of the B-cell lymphoma-2 gene family in A549 cells. These findings indicate that daphnoretin may have potential as a therapeutic agent for the management of lung cancer.
Highlights
Lung cancer is one of the most frequently diagnosed types of cancer and the leading cause of cancer‐associated mortality worldwide [1]
The results revealed that when exposed to daphnoretin, A549 cells underwent the typical morphological changes that are associated with apoptosis
The results demonstrated that daphnoretin inhibited the growth of A549 lung cancer cells in a concentration‐ and time‐dependent manner
Summary
Lung cancer is one of the most frequently diagnosed types of cancer and the leading cause of cancer‐associated mortality worldwide [1]. Despite the development and use of multimodality therapies, including surgery, radiotherapy, conventional chemotherapy and molecular targeted therapy, the clinical outcome of lung cancer treatment remains unsatisfactory, with a five‐year overall survival rate of
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
